

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

PROGRESS ANNOUNCEMENT

**TERMINATION OF THE 2023 H SHARE AWARD AND TRUST
SCHEME AND THE PROPOSED DIRECT REPURCHASE
OF H SHARES FROM THE SCHEME TRUSTEE AND
CANCELLATION OF SUCH H SHARES**

Reference is made to the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated October 30, 2023 (the “**Announcement**”) in relation to, among other things, the termination of the 2023 H Share Award and Trust Scheme and the repurchase and cancellation of H Shares. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

On October 30, 2023, the Board approved the “Proposal on the Termination of the 2023 H Share Award and Trust Scheme of the Company and the Repurchase and Cancellation of H Shares”. In connection with the repurchase and cancellation of H Shares under such proposal, the Company further determined the specific plan to implement the repurchase and cancellation, and the “Proposal on the Direct Repurchase of H Shares in relation to the 2023 H Share Award and Trust Scheme from the Scheme Trustee and the Cancellation of such H Shares” was considered and approved at the sixth meeting of the third session of the Board held on December 12, 2023. In accordance with which, the Company proposes to (i) effect the repurchase of the Acquired Award Shares in the amount of 15,467,500 H Shares by directly repurchasing the same from the Scheme Trustee; and (ii) cancel such 15,467,500 H Shares following the completion of the repurchase and decrease the registered capital of the Company by RMB15,467,500 accordingly (collectively, the “**Proposed Direct Repurchase of H Shares from the Scheme Trustee and Cancellation of such H Shares**”).

In accordance with the applicable laws and regulations including the relevant rules and requirements of the stock exchanges on which the shares of the Company are listed, the Proposed Direct Repurchase of H Shares from the Scheme Trustee and Cancellation of such H Shares shall be subject to the approval by way of special resolutions of (i) the Shareholders at the extraordinary general meeting of the Company (the “**2024 EGM**”); (ii) the A Shareholders at the first A Share class meeting in 2024; and (iii) the H Shareholders at the first H Share class meeting in 2024 (the “**2024 First H Share Class Meeting**”), which will be convened by the Company in due course. Further, as the aforesaid direct repurchase from the Scheme Trustee would not fall under the ambit of the Repurchase Mandate pursuant to the Listing Rules, the Company will not utilize the Repurchase Mandate to effect the Proposed Direct Repurchase of H Shares from the Scheme Trustee and Cancellation of such H Shares.

The Proposed Direct Repurchase of H Shares from the Scheme Trustee and Cancellation of such H Shares will not affect the public float of the Company as required under the Listing Rules, nor will it cause material adverse impact on the operational performance of the Company.

A circular containing, among other things, further details of the (i) the Proposed Direct Repurchase of H Shares from the Scheme Trustee and Cancellation of such H Shares; (ii) the proposed authorization to the Board and for the Board to further authorize the Executive Committee as well as person(s) authorized by the Executive Committee to handle matters pertaining to the Proposed Direct Repurchase of H Shares from the Scheme Trustee and Cancellation of such H Shares; and (iii) notices convening the 2024 EGM and the 2024 First H Share Class Meeting, will be despatched by the Company to the Shareholders in due course.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, December 12, 2023

As at the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* For identification purposes only